Aqueous suspensions of TMC278
This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of HIV infection.
1. A method for producing blood plasma levels of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (TMC278) that are sufficient to treat an HIV infection in an HIV-infected patient comprising:
administering to the patient, by intramuscular or subcutaneous injection, an aqueous suspension comprising
nanoparticles of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (TMC278), or a salt, a stereoisomer or a stereoisomeric mixture thereof,
the particles having a poloxamer adsorbed onto the surfaces thereof, and
the particles having an average effective particle size of below about 1000 nm;
wherein the aqueous suspension is administered intermittently at a time interval that is once every four weeks or once every month; and
wherein the amount of TMC278, or the salt, stereoisomer, or stereoisomeric mixture thereof, in the aqueous suspension is effective in producing a blood plasma level of TMC278 that is sufficient to treat the HIV infection in the patient during the time interval.
2. The method of claim 1 , wherein the amount is calculated on a basis of about 5 mg/day to about 50 mg/day of TMC278.
3. The method of claim 2 , wherein the amount is calculated on a basis of about 10 mg/day to about 25 mg/day.
4. The method of claim 1 , wherein TMC278 is present in base form or in an acid addition salt form.
5. The method of claim 1 , wherein the poloxamer is poloxamer 338.
6. The method of claim 5 , wherein the average effective particle size of the nanoparticles is about 50 nm to about 1000 nm.
7. The method of claim 1 , wherein the amount of TMC278 corresponds with a monthly dose of
a. from about 150 mg to about 1500 mg;
b. from about 30 mg to about 300 mg; or
c. about 300 mg.
8. The method of claim 1 , wherein the aqueous suspension comprises by weight based on the total volume of the composition:
a. from 3% to 50%, from 10% to 40% or from 10 to 30%, of TMC278
b. from 0.5% to 10% or from 0.5% to 2% of the poloxamer;
c. from 0% to 10%, from 0% to 5%, from 0% to 2%, or from 0% to 1% of one of more buffering agents;
d. from 0% to 10%, or from 0% to 6% of an isotonizing agent;
e. from 0% to 2% preservatives; and
f. water for injection q.s. ad 100%.
9. The method of claim 4 , wherein TMC278 is present as the E-isomer of the base form.
10. The method of claim 4 , wherein TMC278 is present as the E-isomer of the acid addition salt form.
11. The method of claim 8 , wherein the buffering agent is tartaric acid, maleic acid, glycine, sodium lactate, lactic acid, ascorbic acid, sodium citrates, citric acid, sodium acetate, acetic acid, sodium bicarbonate, carbonic acid, sodium succinate, succinic acid, sodium benzoate, benzoic acid, sodium phosphates, tris(hydroxymethyl)aminomethane, sodium bicarbonate, sodium carbonate, ammonium hydroxide, benzene sulfonic acid, benzoate sodium, benzoate acid, diethanolamine, glucono delta lactone, hydrochloric acid, hydrogen bromide, lysine, methanesulfonic acid, monoethanolamine, sodium hydroxide, tromethamine, gluconic, glyceric, gluratic, glutamic, ethylene diamine tetraacetic (EDTA), triethanolamine, or a mixture of at least two buffering agents.
12. The method of claim 8 , wherein the isotonizing agent is glucose, dextrose, sucrose, fructose, trehalose, lactose, a polyhydric sugar alcohol, a trihydric or higher sugar alcohol, glycerin, erythritol, arabitol, xylitol, sorbitol, mannitol, sodium chloride or sodium sulfate.
13. The method of claim 1 , wherein the amount of TMC278 is calculated on a basis of about 10 mg/day to about 25 mg/day, TMC278 is present as the E-isomer of the base form, and wherein the poloxamer is poloxamer 338.
14. The method of claim 1 , wherein the average effective nanoparticle size is from about 150 nm to about 220 nm.
15. The method of claim 1 , wherein the relative amount by weight (w/w) of TMC278 to the poloxamer is in the range of 1:2 to about 20:1.
16. The method of claim 15 , wherein the relative amount by weight (w/w) of TMC278 to the poloxamer is about 1:1, about 1:2, about 4:1, about 10:1 or about 20:1.
17. The method of claim 16 , wherein the aqueous suspension is administered by intramuscular injection.
18. The method of claim 17 , wherein the aqueous suspension is administered by intramuscular injection once every four weeks.
19. The method of claim 17 , wherein the aqueous suspension is administered by intramuscular injection once every month.
20. The method of claim 1 , wherein the average effective nanoparticle size is from about 50 nm to about 400 nm.
21. The method of claim 1 , wherein the average effective nanoparticle size is from about 50 nm to about 250 nm.
22. The method of claim 1 , wherein the average effective nanoparticle size is about 400 nm.
23. The method of claim 1 , wherein the average effective nanoparticle size is about 200 nm.